

At page 2, line 11, please insert:

--Detailed Description of the Invention--.

A marked-up copy of the amended specification is not provided herewith inasmuch as all amendments represent added language.

In the Claims:

Please cancel claims 1-4, 7-13 and 16-18. Please amend the claims as follows. Please add new claims 19-29. The following clean claims reflect the amendments being made herein. Pursuant to 37 CFR 1.121(c)(3), a marked-up copy of the amended claims is attached hereto.

5. (Amended) A method of treating neuropathic pain in a mammal comprising administering an effective amount of an EP4 receptor ligand.
6. (Amended) A method of treating colon cancer in a mammal comprising administering an effective amount of an EP4 receptor ligand.
14. (Amended) A method of treating neuropathic pain in a mammal comprising administering an effective amount of an EP4 receptor antagonist.
15. (Amended) A method of treating colon cancer in a mammal comprising administering an effective amount of an EP4 receptor antagonist.
19. (New) The method according to claim 5 wherein said mammal is man.
20. (New) The method according to claim 6 wherein said mammal is man.
21. (New) The method according to claim 5, further comprising administering one or more therapeutic agents selected from the group consisting of a cyclooxygenase 2 (COX-2) inhibitor, a 5-lipoxygenase inhibitor, low dose aspirin, non-steroidal anti-inflammatory drugs (NSAID's), a leukotriene receptor antagonist, disease modifying

anti-rheumatic drugs (DMARD's), an adenosine 1 agonist, a recombinant human tumor necrosis factor (TNF) receptor fusion protein, a sodium channel antagonist, an N-methyl D-aspartate (NMDA) antagonist, and a 5HT1 agonist.

22. (New) A pharmaceutical composition comprising an EP4 receptor ligand and a COX-2 inhibitor.

23. (New) The pharmaceutical composition according to claim 22 further comprising a pharmaceutically acceptable carrier.

24. (New) A pharmaceutical composition comprising an EP4 receptor ligand and one or more therapeutic agents selected from the group consisting of a COX-2 inhibitor, a 5-lipoxygenase inhibitor, low dose aspirin, NSAID's, a leukotriene receptor antagonist, DMARD's, an adenosine 1 agonist, a recombinant human TNF receptor fusion protein, a sodium channel antagonist, an NMDA antagonist, and a 5HT1 agonist.

25. (New) The method according to claim 14, wherein said mammal is man.

26. (New) The method according to claim 15, wherein said mammal is man.

27. (New) A pharmaceutical composition comprising an EP4 receptor antagonist and a COX-2 inhibitor.

28. (New) The pharmaceutical composition according to claim 27 further comprising a pharmaceutically acceptable carrier.

29. (New) A pharmaceutical composition comprising an EP4 receptor antagonist and one or more therapeutic agents selected from the group consisting of a COX-2 inhibitor, a 5-lipoxygenase inhibitor, low dose aspirin, NSAID's, a leukotriene receptor antagonist, DMARD's, an adenosine 1 agonist, a recombinant human TNF receptor